



October 9, 2025

For Immediate Release

Company name: Sanyo Trading Co., Ltd.  
Representative: Masanobu Shintani, President & CEO  
(Code: 3176 TSE Prime Market)  
Inquiries: Yoshimi Namba, Director, Head of Corporate Planning Department  
(Tel: +81-3-3518-1111)

### Notice Regarding Share Acquisition Involving Change in Sub-subsidiaries

Sanyo Trading Co., Ltd. (the "Company") announces that at a meeting of its Board of Directors held today, it passed a resolution regarding YPTECH CO., LTD. ("YPTECH")'s acquisition of all of the shares of Kyushu Mitaka Co., Ltd. ("Kyushu Mitaka"). YPTECH is a subsidiary of the Company. Details are as follows.

#### 1. Reason for the acquisition

With a view toward achieving the Sanyo Vision 2028, its long-term management plan, the Company has selected the strengthening of the Group's earnings base as one of its priority measures, and decided to proceed with the acquisition based on this strategy.

Kyushu Mitaka has more than 40 years of experience in the sale of veterinary pharmaceuticals and functional feeds. It has been operating a business with its own sales channels established centered on Kumamoto Prefecture. The Company has determined that the company is an indispensable partner in YPTECH's moving forward with its business strategy.

With the acquisition of shares, YPTECH's feed business base and Kyushu Mitaka's expertise in the veterinary pharmaceutical business will be combined, enabling YPTECH to provide customers with more convenient services as a total solution provider in the livestock-related business, while also enhancing relationships with business partners.

#### 2. Overview of new second-tier subsidiary

|                    |                                                                                             |
|--------------------|---------------------------------------------------------------------------------------------|
| (1) Name           | Kyushu Mitaka Co., Ltd.                                                                     |
| (2) Location       | 1828 Oyamamachi, Higashi-ku, Kumamoto City, Kumamoto Prefecture                             |
| (3) Representative | Yukihiro Ebihara                                                                            |
| (4) Business       | Sales of veterinary pharmaceuticals, feed additives, veterinary devices and materials, etc. |

|                                                                                      |                                     |                                  |                 |
|--------------------------------------------------------------------------------------|-------------------------------------|----------------------------------|-----------------|
| (5) Share capital                                                                    | 10 million yen                      |                                  |                 |
| (6) Established                                                                      | May 24, 1983                        |                                  |                 |
| (7) Major shareholders and their shareholding ratios                                 | Kyoritsu Holdings Corporation: 100% |                                  |                 |
| (8) Relationship between the listed company and the relevant company                 | Capital relationship                | There are no applicable matters. |                 |
|                                                                                      | Personnel relationship              | There are no applicable matters. |                 |
|                                                                                      | Business relationship               | There are no applicable matters. |                 |
| (9) Operating results and financial position of the company for the last three years |                                     |                                  |                 |
| Fiscal year end                                                                      | FY2023/5                            | FY2024/5                         | FY2025/5        |
| Net assets                                                                           | 350 million yen                     | 361 million yen                  | 377 million yen |
| Total assets                                                                         | 536 million yen                     | 529 million yen                  | 563 million yen |
| Net sales                                                                            | 954 million yen                     | 880 million yen                  | 903 million yen |
| Profit                                                                               | 35 million yen                      | 21 million yen                   | 16 million yen  |

### 3. Number of shares acquired, acquisition price, and status of shares held before and after acquisition

|                                               |                                                                                                                                                                                                                                                                                                                   |
|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) Number of shares held before the transfer | 0 shares                                                                                                                                                                                                                                                                                                          |
| (2) Number of shares acquired                 | 200 shares                                                                                                                                                                                                                                                                                                        |
| (3) Acquisition price                         | The Company is not disclosing the share acquisition price due to a confidentiality agreement concluded between the parties. However, to verify the reasonableness of the value, it has taken sufficient procedures, such as proper due diligence and share value calculations, through third-party organizations. |
| (4) Number of shares held after the transfer  | 200 shares<br>(Percentage of voting rights: 100.0%)                                                                                                                                                                                                                                                               |

### 4. Schedule

|                                      |                            |
|--------------------------------------|----------------------------|
| (1) Date of share transfer agreement | October 9, 2025            |
| (2) Date of share transfer           | October 31, 2025 (planned) |

### 5. Future outlook

The impact of the acquisition of the shares on the consolidated business results for the current fiscal year is minor.